Literature DB >> 10336579

Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.

T S Tracy1, K R Korzekwa, F J Gonzalez, I W Wainer.   

Abstract

AIMS: The present study was conducted to evaluate metabolism of the enantiomers of verapamil and norverapamil using a broad range of cytochrome P450 isoforms and measure the kinetic parameters of these processes.
METHODS: Cytochrome P450 cDNA-expressed cells and microsomes from a P450-expressed lymphoblastoid cell line were incubated with 40 microm concentrations of R- or S-verapamil and R- or S-norverapamil and metabolite formation measured by h.p.l.c. as an initial screening. Those isoforms exhibiting substantial activity were then studied over a range of substrate concentrations (2.5-450 microm ) to estimate the kinetic parameters for metabolite formation.
RESULTS: P450s 3A4, 3A5, 2C8 and to a minor extent 2E1 were involved in the metabolism of the enantiomers of verapamil. Estimated Km values for the production of D-617 and norverapamil by P450 s 3A4 and 3A5 were similar (range=60-127 microm ) regardless of the enantiomer of verapamil studied while the Vmax estimates were also similar (range=4-8 pmol min-1 pmol-1 P450). Only nominal production of D-620 by these isoforms was noted. Interestingly, P450 2C8 readily metabolized both S- and R-verapamil to D-617, norverapamil and PR-22 with only slightly higher Km values than noted for P450s 3A4 and 3A5. However, the Vmax estimates for P450 2C8 metabolism of S- and R-verapamil were in general greater (range=8-15 pmol min-1 pmol-1 P450) than those noted for P450 s 3A4 and 3A5 with preference noted for metabolism of the S-enantiomer. Similarly, P450 s 3A4, 3A5 and 2C8 also mediated the metabolism of the enantiomers of norverapamil with minor contributions by P450 s 2D6 and 2E1. P450s 3A4 and 3A5 readily formed the D-620 metabolite with generally a lower Km and higher Vmax for S-norverapamil than for the R-enantiomer. In contrast, P450 2C8 produced both the D-620 and PR-22 metabolites from the enantiomers of norverapamil, again with stereoselective preference seen for the S-enantiomer.
CONCLUSIONS: These results confirm that P450s 3A4, 3A5 and 2C8 play a major role in verapamil metabolism and demonstrate that norverapamil can also be further metabolized by the P450s.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336579      PMCID: PMC2014179          DOI: 10.1046/j.1365-2125.1999.00923.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2.

Authors:  U Fuhr; B G Woodcock; M Siewert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  First-pass metabolism of cyclosporin by the gut.

Authors:  J C Kolars; W M Awni; R M Merion; P B Watkins
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

4.  Expression of mammalian cytochrome P450 using vaccinia virus.

Authors:  F J Gonzalez; T Aoyama; H V Gelboin
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

5.  The metabolism of DL-[14C]verapamil in man.

Authors:  M Eichelbaum; M Ende; G Remberg; M Schomerus; H J Dengler
Journal:  Drug Metab Dispos       Date:  1979 May-Jun       Impact factor: 3.922

6.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

Authors:  S A Wrighton; W R Brian; M A Sari; M Iwasaki; F P Guengerich; J L Raucy; D T Molowa; M Vandenbranden
Journal:  Mol Pharmacol       Date:  1990-08       Impact factor: 4.436

7.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects.

Authors:  H K Kroemer; H Echizen; H Heidemann; M Eichelbaum
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

8.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Authors:  B Vogelgesang; H Echizen; E Schmidt; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.

Authors:  M F Hebert; J P Roberts; T Prueksaritanont; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1992-11       Impact factor: 6.875

10.  The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.

Authors:  S Kobayashi; S Murray; D Watson; D Sesardic; D S Davies; A R Boobis
Journal:  Biochem Pharmacol       Date:  1989-09-01       Impact factor: 5.858

View more
  28 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

4.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

Review 5.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  The xenobiotic inhibitor profile of cytochrome P4502C8.

Authors:  C E Ong; S Coulter; D J Birkett; C R Bhasker; J O Miners
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

7.  Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

Authors:  P R Mayo; K Skeith; A S Russell; F Jamali
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

8.  Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.

Authors:  Li Liu; Ann C Collier; Jeanne M Link; Karen B Domino; David A Mankoff; Janet F Eary; Charles F Spiekerman; Peng Hsiao; Anand K Deo; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2015-09-09       Impact factor: 3.922

9.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

Review 10.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.